You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Citation Tools

Article menu
Immunotherapy biomarkers
Original research
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhou C, Srivastava MK, Xu H, et al
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Journal for ImmunoTherapy of Cancer 2023;11:e007047. doi: 10.1136/jitc-2023-007047